27 January 2013 - NICE has issued new daft guidance recommending enzalutamide (Xtandi) as an option for treating hormone relapsed metastatic prostate cancer in adults. Enzalutamide works in a different way to other drugs currently available for treating prostate cancer and NICE plans to recommend it as an option for treating hormone relapsed metastatic prostate cancer in adults, only if their disease has progressed during or after a docetaxel-containing chemotherapy regimen, they have not been treated with abiraterone, and the manufacturer provides enzalutamide with the discount agreed in the patient access scheme. In the first draft guidance published in October 2013, enzalutamide was only recommended for people whose disease has progressed during or after one docetaxel-containing chemotherapy regimen. This limitation has now been removed and it is now recommended for people whose disease has progressed during or after any number of docetaxel-containing chemotherapy regimens.
For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICEConsultsAgainDecisionRecommendNewProstateCancerDrug.jsp